1
1859
Biotechnology company focusing on the discovery and development of next-generation therapeutics
About 1859
1859, Inc., founded in 2019 by Devon Cayer, Andrew MacConnell, and Brian M. Paegel, is a biotechnology company headquartered in San Diego, California. The company emerged from stealth mode in February 2022 with a $40 million Series A funding round. Brian M. Paegel, a scientific co-founder, is a Professor at the University of California, Irvine, and his research in parallel synthesis and screening has been instrumental to the company's technological foundation.
The company's business model is centered on partnerships with pharmaceutical and biotechnology companies, as well as academic institutions. 1859 provides its partners with a platform that significantly reduces the time and resources required for compound identification and screening, a critical phase in drug discovery. The company operates in the drug discovery market, serving clients who are developing new therapeutics.
1859's core offering is a technology platform that integrates artificial intelligence with empirical pico-scale screening data to discover new small-molecule medicines. This platform is designed to address emerging disease targets. By combining AI-driven predictions with real-world experimental data, 1859 aims to accelerate the development of new medicines.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- San Diego, United States
- Employees
- 26
- Open positions
- None listed
- Dealroom signal
- 86.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Feb 2022 | $40M | $160M | OMX Ventures · Northpond Ventures · Vertical Venture Partners · FusionX Ventures | ↗ |
| DEBTDebt | Oct 2021 | $2M | — | Undisclosed | — |
Growth signals
Latest recorded traffic for 1859 is 360 monthly website visits, up 71.4% over the last three months. 1859's team grew 18.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
OMX Ventures
Northpond Ventures
Vertical Venture Partners
FusionX Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about 1859 on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See 1859’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.